{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:22:34Z","timestamp":1794270154972,"version":"4.9.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100022910","name":"Australian Society for Antimicrobials","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022910","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijantimicag.2026.107974","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:38:21Z","timestamp":1787614701000},"page":"107974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetics of daptomycin in patients with haematological malignancies and vancomycin-resistant Enterococcus bloodstream infections"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-3972","authenticated-orcid":false,"given":"Kelly A.","family":"Cairns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6646-8844","authenticated-orcid":false,"given":"Zi Xing","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6284-2022","authenticated-orcid":false,"given":"Andrew A.","family":"Udy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2370-2438","authenticated-orcid":false,"given":"Trisha N.","family":"Peel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9788-6650","authenticated-orcid":false,"given":"John","family":"Coutsouvelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushrut","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"McWhinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia B.","family":"Landersdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-2126","authenticated-orcid":false,"given":"Anton Y.","family":"Peleg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107974_bib0001","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00059-22","article-title":"Therapeutics for Vancomycin-resistant enterococcal bloodstream infections","author":"Cairns","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0002","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0003","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","article-title":"Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?","volume":"19","author":"Falcone","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0004","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/cit582","article-title":"Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant staphylococcus aureus bacteremia","volume":"57","author":"Falcone","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0005","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1128\/AAC.02597-15","article-title":"Pharmacokinetic variability of daptomycin during prolonged therapy for bone and joint infections","volume":"60","author":"Goutelle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0006","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jac\/dky541","article-title":"Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection","volume":"74","author":"Bricca","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0007","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/phar.4602","article-title":"Fixed dose daptomycin: an opportunity for pharmacokinetic\/pharmacodynamic optimization in Staphylococcus aureus infections","volume":"44","author":"Olney","year":"2024","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0008","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0009","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1128\/AAC.01321-07","article-title":"Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury","volume":"52","author":"Mohr","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0010","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/AAC.00943-08","article-title":"Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever","volume":"53","author":"Bubalo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0011","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/antibiotics12030515","article-title":"Hypoalbuminemia and pharmacokinetics: when the misunderstanding of a fundamental concept leads to repeated errors over decades","volume":"12","author":"Gandia","year":"2023","journal-title":"Antibiot (Basel)"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0012","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/cid\/ciy749","article-title":"Pharmacodynamic analysis of daptomycin-treated enterococcal bacteremia: it is time to change the breakpoint","volume":"68","author":"Avery","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0013","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113710","article-title":"Daptomycin area under the curve to minimum inhibitory concentration ratio by broth microdilution for predicting the outcome of vancomycin-resistant Enterococcus bloodstream infection","volume":"155","author":"Chuang","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01139-25","article-title":"Risk factors of daptomycin overexposure: a case-control study","volume":"69","author":"Vellat","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0016","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/cid\/ciad386","article-title":"Daptomycin exposure as a risk factor for Daptomycin-induced eosinophilic pneumonia and muscular toxicity","volume":"77","author":"Garreau","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0017","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/cid\/cis210","article-title":"Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer","volume":"54","author":"Theuretzbacher","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0018","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1128\/AAC.02340-14","article-title":"Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy","volume":"58","author":"Sime","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2017.02.032","article-title":"Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic\/pharmacodynamic targets in adult patients with haematological malignancy","volume":"23","author":"Byrne","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0020","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3390\/antibiotics12060979","article-title":"Altered pharmacokinetics parameters of Vancomycin in patients with hematological malignancy with Febrile Neutropenia, a bayesian software estimation","volume":"12","author":"Alzahrani","year":"2023","journal-title":"Antibiot (Basel)"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0021","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0022","series-title":"Introduction to population pharmacokinetic \/pharmacodynamic analysis with nonlinear mixed effects models","author":"Owen","year":"2014"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0023","doi-asserted-by":"crossref","DOI":"10.2147\/DDDT.S581874","article-title":"Advancing daptomycin precision dosing through evaluation of published population pharmacokinetic models and development of a dosing tool","volume":"20","author":"Xie","year":"2026","journal-title":"Drug Devel Ther"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0024","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1093\/jac\/dkx140","article-title":"Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies","volume":"72","author":"Cojutti","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0025","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.kint.2019.12.023","article-title":"How to assess kidney function in oncology patients","volume":"97","author":"Malyszko","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0026","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13977","article-title":"Estimating kidney function in patients with cancer: a narrative review","volume":"238","author":"Claudel","year":"2023","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0027","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jiac.2019.08.017","article-title":"Pharmacokinetics and pharmacodynamics of daptomycin in a clinical setting","volume":"26","author":"Tsukada","year":"2020","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0028","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3390\/antibiotics11070914","article-title":"Daptomycin population pharmacokinetics in patients affected by severe gram-positive infections: an update","volume":"11","author":"Balice","year":"2022","journal-title":"Antibiot (Basel)"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2022.100444","article-title":"Simplified daptomycin dosing regimen for adult patients with methicillin-resistant Staphylococcus aureus infections based on population pharmacokinetic analysis","volume":"44","author":"Yamada","year":"2022","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0030","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jiac.2019.11.002","article-title":"Observational study to determine the optimal dose of daptomycin based on pharmacokinetic\/pharmacodynamic analysis","volume":"26","author":"Yamada","year":"2020","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0032","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaf172","article-title":"Association between daptomycin dosing and in-hospital mortality in patients with vancomycin-resistant Enterococcus faecium bloodstream infection","volume":"7","author":"Cairns","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0033","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/cid\/ciw815","article-title":"Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients","volume":"64","author":"Britt","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0034","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107974_bib0035","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). MIC and Zone diameter distributions website. https:\/\/mic.eucast.org. Accessed February 15, 2026."}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792600261X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792600261X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:39:40Z","timestamp":1794267580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485792600261X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S092485792600261X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107974","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of daptomycin in patients with haematological malignancies and vancomycin-resistant Enterococcus bloodstream infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107974"}}